Quadrivalent vaccine

Newly licensed US manufacturing facility to increase availability of Fluzone® High-Dose Quadrivalent (influenza vaccine)

Retrieved on: 
Thursday, June 17, 2021
Vaccination, Drugs, Vaccines, Medical specialties, Influenza vaccine, Vaccine, Live attenuated influenza vaccine, Sanofi, Influenza, Quadrivalent vaccine, Influenza A virus subtype H3N2

The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.

Key Points: 
  • The newly completed facility further expands production and distribution of Sanofi's Fluzone High-Dose Quadrivalent for the upcoming 2021-2022 influenza season in the United States and will create up to 200 additional manufacturing jobs.
  • Fluzone High-Dose Quadrivalent is a vaccine indicated for prevention of influenza disease caused by influenza A and B strains contained in the vaccine.
  • Vaccination with Fluzone High-Dose Quadrivalent may not protect all people who receive the vaccine.
  • With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.|

Asia Pacific Meningococcal Vaccine Market Report 2021: Bexsero, Trumenba, Nimenrix, Menactra, Menveo - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 17, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Medical specialties, Bacteria, Clinical medicine, Vaccines, Meningococcal vaccine, Sanofi, Meningococcal disease, Neisseria meningitidis, Vaccine, Quadrivalent vaccine, NmVac4-A/C/Y/W-135

The "Asia Pacific Meningococcal Vaccine Market By Brand, By Type, By Age Group, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Meningococcal Vaccine Market By Brand, By Type, By Age Group, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • Meningococcal vaccine manufacturers are focusing on the Asia Pacific region in order to capitalize for broadening treatment options for meningococcal disease in the region.
  • Furthermore, key market players, such as GlaxoSmithKline Plc., are capitalizing more to widening the range of age covered by meningococcal vaccines in the market.
  • Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.

Worldwide Meningococcal Vaccines Industry to 2025 - North America is Expected to Hold Largest Market Share - ResearchAndMarkets.com

Retrieved on: 
Friday, December 18, 2020
Health, Pharmaceutical, Medical specialties, Bacteria, Microbiology, Vaccines, Meningococcal vaccine, Sanofi, Vaccine, Neisseria meningitidis, Quadrivalent vaccine, ATC code J07

Internationally marketed meningococcal polysaccharide vaccines are bivalent (A and C), trivalent (A, C, and W-135) or tetravalent (A, C, Y, and W-135).

Key Points: 
  • Internationally marketed meningococcal polysaccharide vaccines are bivalent (A and C), trivalent (A, C, and W-135) or tetravalent (A, C, Y, and W-135).
  • The vaccines have been helpful in curbing the exponential growth of the disease, and are expected to do so in the future as well.
  • The United States is expected to be the largest meningococcal vaccine market owing to the rising awareness of the disease and the presence of better healthcare infrastructure.
  • Thus, owing to the all above-mentioned factors the Meningococcal Vaccines market is expected to witness steady growth over the forecast period.

2020 Infectious Diseases Disease Analysis - Seasonal Influenza Vaccines - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 9, 2020
Health, Infectious diseases, Vaccination, Drugs, Medical specialties, Vaccines, Influenza vaccines, Influenza vaccine, Vaccine, Influenza, Flu season, Live attenuated influenza vaccine, Seasonal influenza vaccine brands, Quadrivalent vaccine

The "Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Infectious Diseases Disease Analysis: Seasonal Influenza Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • The seasonal influenza vaccines market in the US, Japan, and five major European markets (France, Germany, Italy, Spain, and the UK) is expected to continue to expand over the next 10 years, largely due to the continued uptake of premium-priced vaccines in the elderly subgroup, including quadrivalent forms of Fluzone High-Dose (HD) and Fluad, as well as the launch of the first-in-class adjuvanted nanoparticle vaccine, NanoFlu.
  • Further to this, an aging population in the US, Japan, five major European markets, and other developed countries will increase the number of patients, where coverage rates are higher.
  • Additionally, the COVID-19 pandemic has prompted an unexpected surge in demand for influenza vaccines due to heightened public awareness of the threat posed by respiratory viruses to the elderly and those with co-morbidities, as well as the potential burden on healthcare services of coinciding COVID-19 and influenza waves.

Seqirus Presents Real-World Data for Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) at ESWI 2020

Retrieved on: 
Wednesday, December 9, 2020
Vaccination, Drugs, Medical specialties, Vaccines, Influenza vaccines, Influenza vaccine, Influenza, Vaccine, Live attenuated influenza vaccine, Flu season, Quadrivalent vaccine, Seasonal influenza vaccine brands

"Influenza is an incredibly variable virus, so having real-world data in addition to randomized control trial data allows us to have a better understanding of the effectiveness of seasonal influenza vaccines under varying circumstances."

Key Points: 
  • "Influenza is an incredibly variable virus, so having real-world data in addition to randomized control trial data allows us to have a better understanding of the effectiveness of seasonal influenza vaccines under varying circumstances."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.
  • You should not get FLUCELVAX QUADRIVALENT if you have had a severe allergic reaction to any of the ingredients in the vaccine.
  • The decision to give FLUCELVAX QUADRIVALENT should be made by your healthcare provider, based on careful consideration of the potential benefits and risks.

Medigen and BlueWillow Biologics Partner to Develop Intranasal Vaccine for SARS-CoV-2

Retrieved on: 
Tuesday, November 10, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Life sciences, Health sciences, Vaccination, Vaccines, Biotechnology, Vaccine, Virology, Quadrivalent vaccine, Live attenuated influenza vaccine, Dengue vaccine, Biopharmaceutical, Adjuvant, Medigen Vaccine Biologics (MVC) Corporation, BlueWillow Biologics

Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax adjuvant, today announced a partnership to develop S-2P-NE-01, a nasal vaccine for SARS-CoV-2, the virus that causes COVID-19.

Key Points: 
  • Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, and BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines through its patented NanoVax adjuvant, today announced a partnership to develop S-2P-NE-01, a nasal vaccine for SARS-CoV-2, the virus that causes COVID-19.
  • BlueWillows vaccine technology utilizes a novel oil-in-water nanoemulsion (NE) adjuvant to enable intranasal vaccines for challenging diseases and intranasal immunotherapy (INIT) for food allergies.
  • MVC's pipeline includes enterovirus EV71 vaccine, dengue vaccine, and influenza quadrivalent vaccine, which have all entered late clinical stage.
  • BlueWillow Biologics is a clinical-stage, privately held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform.

Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020

Retrieved on: 
Tuesday, October 20, 2020
Vaccination, Health, Medicine, Vaccines, Medical research, Novavax, COVID-19 vaccine, Influenza vaccines, Vaccine, Live attenuated influenza vaccine, Quadrivalent vaccine, H5N1 clinical trials

GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc.(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Companys COVID-19 vaccine, at the 2020 World Vaccine Congress Europe.

Key Points: 
  • GAITHERSBURG, Md., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc.(Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory M. Glenn, M.D, President of Research & Development, will present on NVX-CoV2373, the Companys COVID-19 vaccine, at the 2020 World Vaccine Congress Europe.
  • For more information on the Congress or to register, please click here .
  • NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.
  • NanoFlu, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.

Seqirus Publishes New Real-World Evidence (RWE) on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Vaccines

Retrieved on: 
Monday, September 21, 2020
Vaccination, Drugs, Medical specialties, Vaccines, RTT, Influenza vaccines, Influenza vaccine, Quadrivalent vaccine, Vaccine, Influenza, Live attenuated influenza vaccine, Adjuvant

The data revealed the all-cause and total influenza-related healthcare costs were comparable among older adults vaccinated with aTIV or a high-dose trivalent influenza vaccine during the 2017/18 influenza season.1 The vaccines included in the economic burden analysis are the only influenza vaccines specifically indicated for patients 65 years and older.

Key Points: 
  • The data revealed the all-cause and total influenza-related healthcare costs were comparable among older adults vaccinated with aTIV or a high-dose trivalent influenza vaccine during the 2017/18 influenza season.1 The vaccines included in the economic burden analysis are the only influenza vaccines specifically indicated for patients 65 years and older.
  • This study evaluated the relative vaccine effectiveness (rVE) of aTIV compared with non-adjuvanted seasonal influenza vaccines including high-dose trivalent vaccine, standard-dose quadrivalent vaccine and standard-dose trivalent vaccine in adults 65 years and older, during the 2017-2018 U.S. influenza season.
  • These new data underscore the importance of RWE to understand how our influenza vaccines work in real world settings."
  • As one of the largest influenza vaccine providers in the world, Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness.

Public flu shots offered Sept. 25 – 27, 9 am – 3 pm, at the Minnesota State Fair grounds

Retrieved on: 
Monday, September 14, 2020
Vaccines, Drugs, Vaccination, RTT, Influenza vaccine, Quadrivalent vaccine, Vaccine, Influenza vaccines, HPV vaccine, Vaccination schedule

Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.

Key Points: 
  • Flu shots will be administered by nurses with Hennepin Healthcares Worksite Wellness program.
  • Two types of flu vaccine are available: Quadrivalent vaccine for people between 6 months-64 years and High Dose vaccine for people age 65 and older.
  • If someone is uninsured, they will receive a free flu shot through the MnVFC (Minnesota Vaccine for Children) or UUAV (Uninsured and Underinsured Adult Vaccine) state program.
  • Health Fair 11s Flu Fighter Clinics are made possible with additional support from Hennepin Healthcare and the Minnesota State Fair.

Vaxess Technologies to Develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen

Retrieved on: 
Monday, September 14, 2020
Health, Infectious diseases, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Vaccination, Medical specialties, Vaccines, Health, RTT, Influenza vaccines, Quadrivalent vaccine, Medical research, Vaccine, Influenza vaccine, Live attenuated influenza vaccine, COVID-19 vaccine, the MIMIX Smart Release Patch Platform, Vaxess Technologies, Medigen Vaccine Biologics Corporation

Vaxess Technologies, an innovative biotechnology company developing the MIMIX smart release patch, has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC) (TPEx: 6547.TWO), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system.

Key Points: 
  • Vaxess Technologies, an innovative biotechnology company developing the MIMIX smart release patch, has formed a partnership with Taiwanese pharmaceutical company, Medigen Vaccine Biologics Corp. (MVC) (TPEx: 6547.TWO), to develop a combined COVID-19 and quadrivalent seasonal influenza vaccine (QIV), delivered via the novel MIMIX patch system.
  • The MIMIX patch is unique in its capacity to enhance vaccine efficacy as well as ease administration and global distribution.
  • Vaxess is combining the novel COVID-19 vaccine with a broadly protective seasonal influenza vaccine into one convenient patch.
  • MVCs pipeline includes enterovirus EV71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all have entered late clinical stage.